In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? Yes; we must beware of drawing conclusions from a subset analysis

Daniel L. Suzman, Emmanuel S. Antonarakis

Research output: Contribution to journalComment/debate

Original languageEnglish (US)
JournalONCOLOGY (United States)
Volume28
Issue number10
StatePublished - Oct 15 2014

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this